Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 7/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.38 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.38 |
| ▸ | GCLC | P48506 | 2/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25660440 | 0.81 | SLC1A3 (0.45) | SLC1A2SLC1A3SLC1A1SLC7A5NOS1 | |
| SCHEMBL25661124 | 0.81 | SLC1A3 (0.45) | SLC1A2SLC1A3SLC1A1SLC7A5NOS1 | |
| SCHEMBL7138120 | 0.80 | SLC7A5 (0.48) | SLC1A2SLC1A3SLC1A1SLC7A5NOS1 | |
| SCHEMBL10436302 | 0.77 | SLC7A5 (0.50) | SLC1A2SLC1A3SLC1A1SLC7A5NOS1 | |
| SCHEMBL722370 | 0.77 | SLC7A5 (0.50) | SLC1A2SLC1A3SLC1A1SLC7A5NOS1 | |
| SCHEMBL1252077 | 0.77 | SLC7A5 (0.50) | SLC1A2SLC1A3SLC1A1SLC7A5NOS1 | |
| SCHEMBL20932872 | 0.77 | SLC7A5 (0.50) | SLC1A2SLC1A3SLC1A1SLC7A5NOS1 | |
| Hydrochloric Acid SCHEMBL23111921 | 0.76 | SLC7A5 (0.48) | SLC1A2SLC1A3SLC1A1SLC7A5NOS1 | |
| SCHEMBL28603100 | 0.76 | SLC7A5 (0.48) | SLC1A2SLC1A3SLC1A1SLC7A5NOS1 | |
| SCHEMBL25661253 | 0.75 | PTGS1 (0.44) | SLC1A2SLC1A3SLC1A1SLC7A5NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180280480-A1 | COMPOSITIONS AND PEPTIDES HAVING DUAL GLP-1R AND GLP-2R AGONIST ACTIVITY | GUBRA APS (DK) | 2018-10-04 | — | — | US | disclosed |
| EP-2190872-B1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK AS (DK) | 2018-03-14 | — | — | EP | disclosed |
| EP-3212217-A1 | COMPOSITIONS AND PEPTIDES HAVING DUAL GLP-1R AND GLP-2R AGONIST ACTIVITY | Gubra ApS (DK) | 2017-09-06 | — | — | EP | disclosed |
| US-9657079-B2 | Truncated GLP-1 derivatives and their therapeutical use | NOVO NORDISK A/S (DK) | 2017-05-23 | — | — | US | disclosed |
| US-9409966-B2 | Glucagon-like peptide-1 derivatives and their pharmaceutical use | NOVO NORDISK A/S (DK) | 2016-08-09 | — | — | US | disclosed |
| WO-2016066818-A1 | COMPOSITIONS AND PEPTIDES HAVING DUAL GLP-1R AND GLP-2R AGONIST ACTIVITY | GUBRA APS (DK) | 2016-05-06 | — | — | WO | disclosed |
| EP-2190873-B1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK AS (DK) | 2015-07-22 | — | — | EP | disclosed |
| US-9067977-B2 | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK A/S (DK) | 2015-06-30 | — | — | US | disclosed |
| EP-2842965-A1 | Neuromedin U analogs comprising serum albumin binding amino acid residue | Gubra ApS (DK) | 2015-03-04 | — | — | EP | disclosed |
| US-20150025003-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK AS (DK) | 2015-01-22 | — | — | US | disclosed |
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK A/S (DK) | 2011-04-07 | — | — | US | disclosed |
| WO-2011033068-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2011-03-24 | — | — | WO | disclosed |
| EP-2293811-A1 | DERIVATISED HYBRID PEPTIDES OF AMYLIN AND SALMON CALCITONIN | Novo Nordisk A/S (DK) | 2011-03-16 | — | — | EP | disclosed |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100261637-A1 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-10-14 | — | — | US | disclosed |
| EP-2190872-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | Novo Nordisk A/S (DK) | 2010-06-02 | — | — | EP | disclosed |
| EP-2190873-A1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | Novo Nordisk A/S (DK) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009156473-A1 | DERIVATISED HYBRID PEPTIDES OF AMYLIN AND SALMON CALCITONIN | NOVO NORDISK A/S (DK) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009030738-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK A/S (DK) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009030774-A1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025003-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLP1R, GIPR, GCGR | SLC1A2 2658/4885SLC1A3 2042/4885SLC1A1 2025/4885 |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | GLP1R, GIPR, IAPP | SLC1A2 1130/4885SLC1A3 419/4885SLC1A1 453/4885 |
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLP1R, GIPR, GCGR | SLC1A2 2658/4885SLC1A3 2042/4885SLC1A1 2025/4885 |
| US-20180280480-A1 | COMPOSITIONS AND PEPTIDES HAVING DUAL GLP-1R AND GLP-2R AGONIST ACTIVITY | GLP1R, GIPR, GCGR | SLC1A2 1725/4885SLC1A3 1557/4885SLC1A1 2022/4885 |
| US-20100261637-A1 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE | GLP1R, IAPP, GIPR | SLC1A2 2022/4885SLC1A3 976/4885SLC1A1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.